JPH10511944A - スーパーオキシドジスムターゼ含有医薬組成物 - Google Patents
スーパーオキシドジスムターゼ含有医薬組成物Info
- Publication number
- JPH10511944A JPH10511944A JP8520616A JP52061696A JPH10511944A JP H10511944 A JPH10511944 A JP H10511944A JP 8520616 A JP8520616 A JP 8520616A JP 52061696 A JP52061696 A JP 52061696A JP H10511944 A JPH10511944 A JP H10511944A
- Authority
- JP
- Japan
- Prior art keywords
- sod
- prolamin
- composition
- group
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000019197 Superoxide Dismutase Human genes 0.000 title claims abstract description 90
- 108010012715 Superoxide dismutase Proteins 0.000 title claims abstract description 90
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 108060006613 prolamin Proteins 0.000 claims abstract description 29
- 229940106189 ceramide Drugs 0.000 claims abstract description 26
- 229920006254 polymer film Polymers 0.000 claims abstract description 8
- 150000001783 ceramides Chemical class 0.000 claims abstract description 7
- 150000002632 lipids Chemical class 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 52
- 241000196324 Embryophyta Species 0.000 claims description 20
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 20
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 19
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 19
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 19
- 239000002502 liposome Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 241000209140 Triticum Species 0.000 claims description 8
- 235000021307 Triticum Nutrition 0.000 claims description 8
- 235000013339 cereals Nutrition 0.000 claims description 7
- 239000004014 plasticizer Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 240000008042 Zea mays Species 0.000 claims description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 5
- 235000005822 corn Nutrition 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 235000013312 flour Nutrition 0.000 claims description 4
- -1 malates Chemical class 0.000 claims description 4
- 235000007319 Avena orientalis Nutrition 0.000 claims description 3
- 244000075850 Avena orientalis Species 0.000 claims description 3
- 240000005979 Hordeum vulgare Species 0.000 claims description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 3
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 235000007238 Secale cereale Nutrition 0.000 claims description 3
- 244000082988 Secale cereale Species 0.000 claims description 3
- 244000062793 Sorghum vulgare Species 0.000 claims description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- 150000002009 diols Chemical class 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 239000012456 homogeneous solution Substances 0.000 claims description 3
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 3
- 150000004701 malic acid derivatives Chemical class 0.000 claims description 3
- 235000019713 millet Nutrition 0.000 claims description 3
- 125000005498 phthalate group Chemical class 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 235000007558 Avena sp Nutrition 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 150000001982 diacylglycerols Chemical class 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 229940116351 sebacate Drugs 0.000 claims description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 210000002377 thylakoid Anatomy 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 abstract description 2
- 210000003743 erythrocyte Anatomy 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 108010061711 Gliadin Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 108010039340 cytochrome C5 Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003279 thiopental Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 101000836247 Aquifex pyrophilus Superoxide dismutase [Fe] Proteins 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940048864 ceramide 1 Drugs 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 125000001549 ceramide group Chemical group 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 本質的にスーパーオキシドジスムターゼと、脂質、タンパク質からなる群 から選択される少なくとも1つの化合物との組み合わせと、及び任意に1以上の 薬理学的に受容し得る賦形剤からなることを特徴とする医薬組成物。 2. 脂質が、セラミド、リン脂質、チラコイド及びジアシルグリセロールから なる群から選択され、タンパク質が、プロラミン及びプロラミンベースのポリマ ーフィルムからなる群から選択されることを特徴とする、請求項1に記載の組成 物。 3. セラミド(又はN−アシルスフィンゴシン)が、植物起源であり、式 〔式中、nは5〜15、好ましくは12〜15であり、 Xは、−CH=CH−か−CHOH−であり、 Rは、水素原子か糖(グルコース、ガラクトース)であり、かつ、R’は、C3 −C30アルキル基である〕 のスフィンゴシンのN−アシル脂肪酸誘導体であることを特徴とする、請求項2 に記載の組成物。 4. 植物起源のセラミドが、好ましくは穀類(穀粉)、特に小麦から誘導され 、下記式 〔式中、Rは、水素原子かグルコースであり、かつR’は、上記のとおりである 〕 を有することを特徴とする、請求項3に記載の組成物。 5. プロラミンが植物起源であり、小麦、ライ麦、大麦、エンバク、米、キビ 及びトウモロコシからなる群から選択される種々の穀類から誘導されることを特 徴とする、請求項2に記載の組成物。 6. プロラミンベースのポリマーフィルムが、好ましくは −少なくとも1つの植物起源のプロラミン、 −炭水化物、好ましくはポリオール類と、フタル酸エステル、アジピン酸エステ ル、セバシン酸エステル、リン酸エステル、クエン酸エステル、酒石酸エステル 、リンゴ酸エステルのようなエステル類からなる群から選択され、プロラミンと の比が2:1〜2:0.5である少なくとも1つの可塑剤、及び −モノオール、ジオール及び水から選択される5〜30%の少なくとも1つの溶 媒、 からなる疎水性ポリマーからなり、 −それらが、アルコール力値40〜80%の水性アルコール溶媒に溶解した40 〜80%の少なくとも1つのプロラミンと、アルコールプロラミン溶液との比が 0.10:1〜0.50:1、好ましくは0.20:1〜0.23:1である少 なくとも 1つの可塑剤からなる原料組成物の存在する溶媒の少なくとも一部を、より濃い 又は薄い濃度の均一溶液が得られるまで蒸発させて得ることができることを特徴 とする、請求項1に記載の組成物。 7. 経口投与用の請求項1〜6のいずれか1つに記載の組成物。 8. 結合賦形剤としてリポソームを含むことを特徴とする、請求項1〜7のい ずれか1つに記載の組成物。 9. 少なくとも炎症治療用医薬の製造のための、請求項1〜8のいずれか1つ に記載の組成物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9500309A FR2729296B1 (fr) | 1995-01-12 | 1995-01-12 | Compositions pharmaceutiques comprenant une superoxyde dismutase |
FR95/00309 | 1995-01-12 | ||
PCT/FR1996/000055 WO1996021462A1 (fr) | 1995-01-12 | 1996-01-12 | Compositions pharmaceutiques comprenant une superoxyde dismutase |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10511944A true JPH10511944A (ja) | 1998-11-17 |
JP3856825B2 JP3856825B2 (ja) | 2006-12-13 |
Family
ID=9475077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52061696A Expired - Lifetime JP3856825B2 (ja) | 1995-01-12 | 1996-01-12 | スーパーオキシドジスムターゼ含有医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US6045809A (ja) |
EP (1) | EP0804225B1 (ja) |
JP (1) | JP3856825B2 (ja) |
AT (1) | ATE209504T1 (ja) |
DE (1) | DE69617395T2 (ja) |
ES (1) | ES2168457T3 (ja) |
FR (1) | FR2729296B1 (ja) |
WO (1) | WO1996021462A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002518417A (ja) * | 1998-06-25 | 2002-06-25 | ラヴィファム ラボラトリーズ インコーポレーテッド | 勃起機能不全の治療装具及び方法 |
JP2005336072A (ja) * | 2004-05-25 | 2005-12-08 | Combi Corp | 腎障害抑制剤 |
JP2006504628A (ja) * | 2002-04-19 | 2006-02-09 | ビオグルト ビオガルデ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト | 生体活性のリン脂質含有成分を含有するマトリックス |
JP2006062976A (ja) * | 2004-08-24 | 2006-03-09 | Nippon Medical School | 筋肉の酸化ストレス軽減用経口剤 |
WO2009104649A1 (ja) * | 2008-02-22 | 2009-08-27 | 片山化学工業株式会社 | 合成糖脂質含有リポソーム |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2759288A1 (fr) * | 1997-02-12 | 1998-08-14 | Gredeco Groupe De Rech En Derm | Nouveau gel a base de gliadine |
WO1999017738A1 (en) * | 1997-10-03 | 1999-04-15 | Lavipharm Laboratories, Inc. | A prolamine-plant polar lipid composition, its method of preparation and applications thereof |
FR2770843B1 (fr) * | 1997-11-13 | 2000-01-14 | Lavipharm Lab | Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications |
FR2820323B1 (fr) * | 2001-02-07 | 2004-10-08 | Innoform Sa | Composition dietetique et cosmetique a base de polymeres vegetaux immobilisant des actifs |
FR2822381B1 (fr) | 2001-03-20 | 2004-10-22 | Bio Obtention Sc | Extrait de cucumis melo enrobe et/ou microencapsule dans un agent liposoluble a base de matiere grasse |
US6503506B1 (en) * | 2001-08-10 | 2003-01-07 | Millenium Biotechnologies, Inc. | Nutrient therapy for immuno-compromised patients |
JP2004099459A (ja) * | 2002-09-05 | 2004-04-02 | Asama Chemical Co Ltd | 抗腫瘍剤 |
US20060239987A1 (en) * | 2005-04-22 | 2006-10-26 | Robert Foster | Nutritional composition and methods of making and using same |
US20060257493A1 (en) * | 2005-04-28 | 2006-11-16 | Amiji Mansoor M | Nanoparticulate delivery systems for treating multi-drug resistance |
GB0603975D0 (en) * | 2006-03-01 | 2006-04-05 | Etren | Methods and agents for reducing oxidative stress |
CA2645674A1 (en) * | 2006-03-15 | 2007-09-20 | Isocell Pharma S.A. | Pharmaceutical compositions comprising sods and prolamine based peptide fragments |
US20080119386A1 (en) * | 2006-11-22 | 2008-05-22 | Carl Germano | Nutritional formula for athletes' recovery |
EP2433640B1 (en) | 2010-09-24 | 2020-01-15 | OmniVision GmbH | Composition comprising SOD, lutein and zeaxanthin |
KR102230514B1 (ko) * | 2013-03-07 | 2021-03-19 | 바마르사 리서치 엘엘씨 | 글리아딘 펩타이드를 사용한 암 치료용 키트 및 방법 |
FR3031040B1 (fr) | 2014-12-29 | 2018-09-07 | Universite De Bretagne Occidentale | Procede d'obtention d'un extrait proteique concentre en superoxydase dismutase (sod) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0292964B1 (en) * | 1987-05-28 | 1995-04-05 | Hiroshi Maeda | Superoxide dismutase derivatives a method of producing the same and medicinal use of the same |
JPH0262829A (ja) * | 1988-05-18 | 1990-03-02 | Nippon Kayaku Co Ltd | 虚血に基づく傷害の予防及び治療剤 |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US5271961A (en) * | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
JP2937446B2 (ja) * | 1990-09-14 | 1999-08-23 | 株式会社資生堂 | 白髪防止黒化剤 |
FR2711138B1 (fr) * | 1993-10-12 | 1995-11-24 | Oreal | Céramides, leur procédé de préparation et leurs applications en cosmétique et en dermopharmacie. |
-
1995
- 1995-01-12 FR FR9500309A patent/FR2729296B1/fr not_active Expired - Lifetime
-
1996
- 1996-01-12 AT AT96901386T patent/ATE209504T1/de not_active IP Right Cessation
- 1996-01-12 DE DE69617395T patent/DE69617395T2/de not_active Expired - Fee Related
- 1996-01-12 ES ES96901386T patent/ES2168457T3/es not_active Expired - Lifetime
- 1996-01-12 US US08/860,965 patent/US6045809A/en not_active Expired - Lifetime
- 1996-01-12 EP EP96901386A patent/EP0804225B1/fr not_active Revoked
- 1996-01-12 JP JP52061696A patent/JP3856825B2/ja not_active Expired - Lifetime
- 1996-01-12 WO PCT/FR1996/000055 patent/WO1996021462A1/fr not_active Application Discontinuation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002518417A (ja) * | 1998-06-25 | 2002-06-25 | ラヴィファム ラボラトリーズ インコーポレーテッド | 勃起機能不全の治療装具及び方法 |
JP2006504628A (ja) * | 2002-04-19 | 2006-02-09 | ビオグルト ビオガルデ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト | 生体活性のリン脂質含有成分を含有するマトリックス |
JP2005336072A (ja) * | 2004-05-25 | 2005-12-08 | Combi Corp | 腎障害抑制剤 |
JP2006062976A (ja) * | 2004-08-24 | 2006-03-09 | Nippon Medical School | 筋肉の酸化ストレス軽減用経口剤 |
WO2009104649A1 (ja) * | 2008-02-22 | 2009-08-27 | 片山化学工業株式会社 | 合成糖脂質含有リポソーム |
JP5465542B2 (ja) * | 2008-02-22 | 2014-04-09 | 片山化学工業株式会社 | 合成糖脂質含有リポソーム |
Also Published As
Publication number | Publication date |
---|---|
ATE209504T1 (de) | 2001-12-15 |
JP3856825B2 (ja) | 2006-12-13 |
WO1996021462A1 (fr) | 1996-07-18 |
FR2729296A1 (fr) | 1996-07-19 |
DE69617395T2 (de) | 2002-08-22 |
ES2168457T3 (es) | 2002-06-16 |
EP0804225A1 (fr) | 1997-11-05 |
DE69617395D1 (de) | 2002-01-10 |
EP0804225B1 (fr) | 2001-11-28 |
FR2729296B1 (fr) | 1997-03-28 |
US6045809A (en) | 2000-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3856825B2 (ja) | スーパーオキシドジスムターゼ含有医薬組成物 | |
US5051406A (en) | Pharmaceutical composition using albumin as a carrier and process for producing the same | |
AU666931B2 (en) | Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate | |
CA2019974C (en) | Treatment of inflammation | |
FI92905B (fi) | Menetelmä eläinperäisen keuhkojen pinta-aktiivisen aineen valmistamiseksi | |
KR100658436B1 (ko) | 아데노실코발라민 함유 피부질환 치료용 외용제 조성물 | |
CA1322956C (en) | Process for the production of dried earthworm powder and antihyperlipemic, antidiabetic, antihypertensive and antihypotensive preparations containing dried earthworm powder as active ingredient | |
JP2001510451A (ja) | 弱塩基性薬物を担持するイオン運搬体―中介リポゾーム | |
TW201102083A (en) | Improved reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C) | |
WO2021196659A1 (zh) | 糖基聚醚类化合物脂质体及其制备方法和药物 | |
EP0351651B1 (en) | Insulin preparation | |
BG100554A (bg) | Нов синтетичен пептид, съдържащо пептида белодробно повърхностно активно вещество и лекарствено средство за лечение на дихателна недостатъчност | |
JP2008517023A (ja) | アルキルホスホコリンを含有する新規の負電荷担体を使用した配合物 | |
EA010650B1 (ru) | Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек | |
RU2538597C2 (ru) | Органические соединения для регуляции векторных ионных каналов | |
WO2014127245A1 (en) | Treatment of klebsiella pneumoniae with liposomally formulated glutathione | |
DK173610B1 (da) | Stabil, parenteral opløsning af 2-phenyl-1,2-benzisoselenazol-3(2H)-on og fremgangsmåde til fremstilling deraf | |
CA2671668A1 (en) | Therapeutic composition for interstitial pheumonia | |
JP2003528134A (ja) | 白血球産生の刺激用および腫瘍および原虫症の治療用およびダニ症、節足動物媒介感染の治療用医薬組成物およびその製法 | |
JPH10245346A (ja) | リポソーマル人カルシトニン遺伝子関係ペプチド組成物及びその製造方法 | |
RU2184564C2 (ru) | Лекарственный гель | |
RU2213746C1 (ru) | Компонент, обеспечивающий поверхностно-активные свойства композиций - аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний | |
CN109364067B (zh) | 一种化合物在制备提高血脑屏障通透性药物中的用途 | |
WO1997036598A1 (en) | Use of aminoalkylcarboxylic derivatives | |
JPH04210631A (ja) | 消化管壁保護剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060411 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060710 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060829 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060913 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090922 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100922 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100922 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110922 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120922 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120922 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130922 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |